243 related articles for article (PubMed ID: 25288776)
1. JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.
Chen E; Ahn JS; Massie CE; Clynes D; Godfrey AL; Li J; Park HJ; Nangalia J; Silber Y; Mullally A; Gibbons RJ; Green AR
Proc Natl Acad Sci U S A; 2014 Oct; 111(42):15190-5. PubMed ID: 25288776
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
[TBL] [Abstract][Full Text] [Related]
3. Comparison of checkpoint responses triggered by DNA polymerase inhibition versus DNA damaging agents.
Liu JS; Kuo SR; Melendy T
Mutat Res; 2003 Nov; 532(1-2):215-26. PubMed ID: 14643438
[TBL] [Abstract][Full Text] [Related]
4. Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation.
Stetka J; Vyhlidalova P; Lanikova L; Koralkova P; Gursky J; Hlusi A; Flodr P; Hubackova S; Bartek J; Hodny Z; Divoky V
Oncogene; 2019 Jul; 38(28):5627-5642. PubMed ID: 30967632
[TBL] [Abstract][Full Text] [Related]
5. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.
Marcellino BK; Hoffman R; Tripodi J; Lu M; Kosiorek H; Mascarenhas J; Rampal RK; Dueck A; Najfeld V
Blood Adv; 2018 Dec; 2(24):3581-3589. PubMed ID: 30563882
[TBL] [Abstract][Full Text] [Related]
6. Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders.
Ayad MW; Nafea D
Genet Test Mol Biomarkers; 2011; 15(1-2):17-21. PubMed ID: 21034166
[TBL] [Abstract][Full Text] [Related]
7. JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2.
Kagoya Y; Yoshimi A; Tsuruta-Kishino T; Arai S; Satoh T; Akira S; Kurokawa M
Blood; 2014 Nov; 124(19):2996-3006. PubMed ID: 25217696
[TBL] [Abstract][Full Text] [Related]
8. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
9. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
10. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.
de Melo Campos P; Machado-Neto JA; Eide CA; Savage SL; Scopim-Ribeiro R; da Silva Souza Duarte A; Favaro P; Lorand-Metze I; Costa FF; Tognon CE; Druker BJ; Olalla Saad ST; Traina F
Oncotarget; 2016 Feb; 7(6):6948-59. PubMed ID: 26755644
[TBL] [Abstract][Full Text] [Related]
11. JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation.
Ahn JS; Li J; Chen E; Kent DG; Park HJ; Green AR
Oncogene; 2016 Apr; 35(17):2235-46. PubMed ID: 26234675
[TBL] [Abstract][Full Text] [Related]
12. IL-6 stimulation of DNA replication is JAK1/2 mediated in cross-talk with hyperactivated ERK1/2 signaling.
Subotički T; Mitrović Ajtić O; Beleslin-Čokić BB; Bjelica S; Djikić D; Diklić M; Leković D; Gotić M; Santibanez JF; Noguchi CT; Čokić VP
Cell Biol Int; 2019 Feb; 43(2):192-206. PubMed ID: 30571852
[TBL] [Abstract][Full Text] [Related]
13. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.
Marty C; Lacout C; Droin N; Le Couédic JP; Ribrag V; Solary E; Vainchenker W; Villeval JL; Plo I
Leukemia; 2013 Nov; 27(11):2187-95. PubMed ID: 23558526
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms.
Baumeister J; Chatain N; Hubrich A; Maié T; Costa IG; Denecke B; Han L; Küstermann C; Sontag S; Seré K; Strathmann K; Zenke M; Schuppert A; Brümmendorf TH; Kranc KR; Koschmieder S; Gezer D
Leukemia; 2020 Apr; 34(4):1062-1074. PubMed ID: 31728053
[TBL] [Abstract][Full Text] [Related]
15. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.
Lussana F; Carobbio A; Salmoiraghi S; Guglielmelli P; Vannucchi AM; Bottazzi B; Leone R; Mantovani A; Barbui T; Rambaldi A
J Hematol Oncol; 2017 Feb; 10(1):54. PubMed ID: 28228104
[TBL] [Abstract][Full Text] [Related]
16. The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up.
Kurtovic-Kozaric A; Islamagic E; Komic H; Bilalovic N; Eminovic I; Burekovic A; Uzunovic A; Kurtovic S
Bosn J Basic Med Sci; 2020 May; 20(2):236-247. PubMed ID: 31668145
[TBL] [Abstract][Full Text] [Related]
17. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
18. JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms.
Nakatake M; Monte-Mor B; Debili N; Casadevall N; Ribrag V; Solary E; Vainchenker W; Plo I
Oncogene; 2012 Mar; 31(10):1323-33. PubMed ID: 21785463
[TBL] [Abstract][Full Text] [Related]
19. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
20. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
